Risk Factors Associated With Post−COVID-19 Condition

JAMA Internal Medicine, Journal Year: 2023, Volume and Issue: 183(6), P. 566 - 566

Published: March 23, 2023

Post-COVID-19 condition (PCC) is a complex heterogeneous disorder that has affected the lives of millions people globally. Identification potential risk factors to better understand who at developing PCC important because it would allow for early and appropriate clinical support.To evaluate demographic characteristics comorbidities have been found be associated with an increased PCC.Medline Embase databases were systematically searched from inception December 5, 2022.The meta-analysis included all published studies investigated and/or predictors in adult (≥18 years) patients.Odds ratios (ORs) each factor pooled selected studies. For factor, random-effects model was used compare between individuals without factor. Data analyses performed 2022, February 10, 2023.The patient age; sex; body mass index, calculated as weight kilograms divided by height meters squared; smoking status; comorbidities, including anxiety depression, asthma, chronic kidney disease, obstructive pulmonary diabetes, immunosuppression, ischemic heart disease; previous hospitalization or ICU (intensive care unit) admission COVID-19; vaccination against COVID-19.The initial search yielded 5334 records which 255 articles underwent full-text evaluation, identified 41 total 860 783 patients included. The findings showed female sex (OR, 1.56; 95% CI, 1.41-1.73), age 1.21; 1.11-1.33), high BMI 1.15; 1.08-1.23), 1.10; 1.07-1.13) PCC. In addition, presence 2.48; 1.97-3.13 OR, 2.37; 2.18-2.56, respectively). Patients had vaccinated COVID-19 2 doses significantly lower compared not 0.57; 0.43-0.76).This systematic review demonstrated certain (eg, sex), severe PCC, whereas protective role sequelae. These may enable understanding develop provide additional evidence benefits vaccination.PROSPERO Identifier: CRD42022381002.

Language: Английский

---

The immunology of long COVID

Nature reviews. Immunology, Journal Year: 2023, Volume and Issue: 23(10), P. 618 - 634

Published: July 11, 2023

Language: Английский

---

Effect of covid-19 vaccination on long covid: systematic review

BMJ Medicine, Journal Year: 2023, Volume and Issue: 2(1), P. e000385 - e000385

Published: Feb. 1, 2023

To determine the effect of covid-19 vaccination, given before and after acute infection with SARS-CoV-2 virus, or a diagnosis long covid, on rates symptoms covid.Systematic review.PubMed, Embase, Cochrane trials, Europe PubMed Central (Europe PMC) for preprints, from 1 January 2020 to 3 August 2022.Trials, cohort studies, case-control studies reporting patients covid vaccination covid. Risk bias was assessed ROBINS-I tool.1645 articles were screened but no randomised controlled trials found. 16 observational five countries (USA, UK, France, Italy, Netherlands) identified that reported 614 392 patients. The most common studied fatigue, cough, loss sense smell, shortness breath, taste, headache, muscle ache, difficulty sleeping, concentrating, worry anxiety, memory confusion. 12 data 10 showed significant reduction in incidence covid: odds ratio developing one dose vaccine ranged 0.22 1.03; two doses, ratios 0.25-1; three 0.16; any dose, 0.48-1.01. Five infection, 0.38-0.91. high heterogeneity between precluded meaningful meta-analysis. failed adjust potential confounders, such as other protective behaviours missing data, thus increasing risk decreasing certainty evidence low.Current suggest vaccines might have therapeutic effects More robust comparative are needed, however, clearly effectiveness preventing treating covid.Open Science Framework https://osf.io/e8jdy.

Language: Английский

---

Post-acute sequelae of covid-19 six to 12 months after infection: population based study

BMJ, Journal Year: 2022, Volume and Issue: unknown, P. e071050 - e071050

Published: Oct. 13, 2022

Abstract Objectives To describe symptoms and symptom clusters of post-covid syndrome six to 12 months after acute infection, risk factors, examine the association with general health working capacity. Design Population based, cross sectional study Setting Adults aged 18-65 years confirmed SARS-CoV-2 infection between October 2020 March 2021 notified authorities in four geographically defined regions southern Germany. Participants 50 457 patients were invited participate study, whom 053 (24%) responded 11 710 (58.8% (n=6881) female; mean age 44.1 years; 3.6% (412/11 602) previously admitted covid-19; follow-up time 8.5 months) could be included analyses. Main outcome measures Symptom frequencies (six versus before infection), severity clustering, associations recovery Results The fatigue (37.2% (4213/11 312), 95% confidence interval 36.4% 38.1%) neurocognitive impairment (31.3% (3561/11 361), 30.5% 32.2%) contributed most reduced capacity, but chest symptoms, anxiety/depression, headache/dizziness, pain syndromes also prevalent relevant for some differences according sex age. Considering new at least moderate daily life ≤80% recovered or overall estimate was 28.5% (3289/11 536, 27.7% 29.3%) among participants 6.5% (3289/50 457) infected adult population (assuming that all non-responders had completely recovered). true value is likely these estimates. Conclusions Despite limitation a low response rate possible selection recall biases, this suggests considerable burden self-reported post-acute sequelae, notably impairment, even young middle adults mild substantial impact on Trial registration German registry clinical studies DRKS 00027012.

Language: Английский

---

The Costs of Long COVID

JAMA Health Forum, Journal Year: 2022, Volume and Issue: 3(5), P. e221809 - e221809

Published: May 12, 2022

More than 6 million people have died from COVID-19 worldwide, including nearly 1 in the US.1 But mortality is not only adverse consequence of COVID-19. Many survivors suffer long-term impairment, officially termed postacute sequelae SARS-CoV-2 infection and commonly called long COVID.

Language: Английский

---

Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Oct. 12, 2022

Language: Английский

---

Blood–brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment

Nature Neuroscience, Journal Year: 2024, Volume and Issue: 27(3), P. 421 - 432

Published: Feb. 22, 2024

Abstract Vascular disruption has been implicated in coronavirus disease 2019 (COVID-19) pathogenesis and may predispose to the neurological sequelae associated with long COVID, yet it is unclear how blood–brain barrier (BBB) function affected these conditions. Here we show that BBB evident during acute infection patients COVID cognitive impairment, commonly referred as brain fog. Using dynamic contrast-enhanced magnetic resonance imaging, COVID-associated Transcriptomic analysis of peripheral blood mononuclear cells revealed dysregulation coagulation system a dampened adaptive immune response individuals Accordingly, showed increased adhesion human endothelial vitro, while exposure serum from induced expression inflammatory markers. Together, our data suggest sustained systemic inflammation persistent localized dysfunction key feature

Language: Английский

---

Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(24), P. 7314 - 7314

Published: Dec. 9, 2022

Identification of predictors long COVID-19 is essential for managing healthcare plans patients. This systematic literature review and meta-analysis aimed to identify risk factors not associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, but rather potentially predictive the development COVID-19. MEDLINE, CINAHL, PubMed, EMBASE, Web Science databases, as well medRxiv bioRxiv preprint servers were screened through 15 September 2022. Peer-reviewed studies or preprints evaluating potential pre-SARS-CoV-2 infection long-lasting symptoms included. The methodological quality was assessed using Quality in Prognosis Studies (QUIPSs) tool. Random-effects meta-analyses calculation odds ratio (OR) performed those where a homogenous definition used. From 1978 identified, 37 peer-reviewed one Eighteen articles evaluated age, sixteen sex, twelve medical comorbidities Overall, single reported that old age seems be (n = 18); however, did reveal an association between 3; OR 0.86, 95% CI 0.73 1.03, p 0.17). Similarly, revealed female sex 16); which confirmed 7; 1.48, 1.17 1.86, 0.01). Finally, such pulmonary disease 4), diabetes 1), obesity 6), organ transplantation 1) also identified bias most (71%, n 27/38) moderate high. In conclusion, pooled evidence support advancing supported factor Long some previous comorbidities.

Language: Английский

---

Long covid—an update for primary care

BMJ, Journal Year: 2022, Volume and Issue: unknown, P. e072117 - e072117

Published: Sept. 22, 2022

Ziauddeen N, Gurdasani D, O’Hara ME, et al. Characteristics of long covid: findings from a social media survey.medRxiv2021 [Preprint] doi:10.1136/jech-2021-SSMabstracts.194.

Language: Английский

---

Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study

BMJ, Journal Year: 2023, Volume and Issue: unknown, P. e074425 - e074425

Published: May 31, 2023

To evaluate longer term symptoms and health outcomes associated with post-covid-19 condition within a cohort of individuals SARS-CoV-2 infection.Population based, longitudinal cohort.General population canton Zurich, Switzerland.1106 adults confirmed infection who were not vaccinated before 628 did have an infection.Trajectories self-reported status covid-19 related between months six, 12, 18, 24 after excess risk at six compared had no infection.22.9% (95% confidence interval 20.4% to 25.6%) infected fully recover by months. The proportion reported having recovered decreased 18.5% (16.2% 21.1%) 12 17.2% (14.0% 20.8%) infection. When assessing changes in status, most participants continued recovery (68.4% (63.8% 72.6%)) or overall improvement (13.5% (10.6% 17.2%)) over time. Yet, 5.2% (3.5% 7.7%) worsening 4.4% (2.9% 6.7%) alternating periods impairment. point prevalence severity also time, 18.1% (14.8% 21.9%) reporting 8.9% (6.5% 11.2%) all four follow-up time points, while 12.5% (9.8% 15.9%) alternatingly absent present. Symptom was higher among those (adjusted difference 17.0% (11.5% 22.4%)). Excess difference) for individual ranged from 2% 10%, the highest risks observed altered taste smell (7.7% 11.8%)), post-exertional malaise (9.4% (6.1% 12.7%)), fatigue (5.4% (1.2% 9.5%)), dyspnoea (7.8% (5.2% 10.4%)), reduced concentration (8.3% (6.0% 10.7%)) memory (5.7% 7.9%)).Up 18% up two years infection, evidence symptom controls. Effective interventions are needed reduce burden condition. Use multiple outcome measures consideration expected rates heterogeneity trajectories important design interpretation clinical trials.ISRCTN18181860, .

Language: Английский

---